Corcept Therapeutics (CORT) Q2 FY26 earnings call

Corcept Therapeutics delivered a strong second quarter, driven by the successful launch of Lifyorli for platinum-resistant ovarian cancer and continued robust demand for Korlym. The company raised its full-year revenue guidance, reflecting confidence in both its endocrinology and oncology segments. Significant pipeline progress was also highlighted across multiple therapeutic areas.